Agilon Health (NYSE:AGL) Announces Earnings Results

Agilon Health (NYSE:AGL) issued its earnings results on Wednesday. The company reported ($0.46) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.27) by ($0.19), Zacks reports. Agilon Health had a negative return on equity of 75.92% and a negative net margin of 5.24%.

Here are the key takeaways from Agilon Health’s conference call:

• 2026 guidance: Management expects revenue around $5.5B (midpoint), medical margin ~$325M and adjusted EBITDA roughly breakeven at the midpoint, with platform membership targeted at 525k–540k (MA ~430k, ACO ~103k) and a net cost-trend assumption near 7%.
• Operational progress includes an enhanced data pipeline (member-level risk scoring covering >85% of members), AI-assisted Burden of Illness identification, and clinical pathways (CHF active in >90% of the network) that management says will improve risk capture, utilization and quality.
• 2025 financials were weak—full-year adjusted EBITDA of -$296M and medical margin of -$57M—driven by elevated cost trends (~6.5%) and several large inpatient claims, leading the company to exit unprofitable payer contracts and reduce MA membership (to ~430k, including ~25k on care-coordination fee arrangements).
• Liquidity and policy outlook: year-end cash of $285M (plus $91M ACO-held cash) with an extended credit facility and a plan to finish 2026 with at least $125M, while management warns the CMS Advance Notice may understate cost trends but believes its BOI/clinical initiatives can mitigate much of the risk-model impact.

Agilon Health Trading Up 31.0%

Shares of Agilon Health stock traded up $0.12 on Wednesday, hitting $0.52. The stock had a trading volume of 11,649,776 shares, compared to its average volume of 7,832,561. The stock has a market cap of $214.07 million, a price-to-earnings ratio of -0.69 and a beta of 0.06. The company’s 50 day moving average price is $0.72 and its 200 day moving average price is $0.86. Agilon Health has a 52-week low of $0.34 and a 52-week high of $6.08.

Key Headlines Impacting Agilon Health

Here are the key news stories impacting Agilon Health this week:

• Neutral Sentiment: Company released quarterly results and published its press release and slide deck (Feb. 25). Investors can review the filings and presentation for management commentary and any updated guidance. View Press Release
• Negative Sentiment: Earnings missed analyst expectations: Agilon reported EPS of ($0.46) vs. consensus ($0.27), missing by $0.19. The release showed a negative net margin (~5.24%) and a deeply negative ROE (~-75.9%), underscoring continued profitability and execution challenges. These results explain investor concern and help justify increased trading volume. Earnings Press Release & Slides
• Negative Sentiment: Numerous law firms have filed investor alerts and class‑action notices alleging securities fraud tied to Agilon and are soliciting lead‑plaintiff candidates; the common class period cited is Feb. 26, 2025–Aug. 4, 2025 and the lead‑plaintiff deadline is March 2, 2026. The volume of notices (Rosen, Glancy, Levi & Korsinsky, Faruqi, Pomerantz, Bragar, and others) increases legal risk and creates a persistent overhang that can suppress the stock until resolution or clearer disclosure. Rosen Law Firm Notice

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the business. Barclays PLC lifted its stake in Agilon Health by 7.6% in the 4th quarter. Barclays PLC now owns 528,613 shares of the company’s stock valued at $364,000 after buying an additional 37,478 shares in the last quarter. Cerity Partners LLC purchased a new stake in Agilon Health in the 4th quarter worth approximately $277,000. Wells Fargo & Company MN raised its stake in Agilon Health by 78.0% during the fourth quarter. Wells Fargo & Company MN now owns 337,624 shares of the company’s stock worth $233,000 after purchasing an additional 147,921 shares during the period. Mariner LLC grew its holdings in shares of Agilon Health by 435.6% during the 4th quarter. Mariner LLC now owns 238,513 shares of the company’s stock worth $166,000 after purchasing an additional 193,978 shares during the period. Finally, WINTON GROUP Ltd acquired a new position in Agilon Health during the 2nd quarter worth approximately $106,000.

Analysts Set New Price Targets

Several equities analysts have commented on the company. Barclays cut their price objective on Agilon Health from $1.50 to $1.00 and set an “underweight” rating on the stock in a research report on Thursday, November 6th. Royal Bank Of Canada raised Agilon Health from a “hold” rating to a “moderate buy” rating in a research report on Wednesday, December 3rd. Weiss Ratings restated a “sell (e+)” rating on shares of Agilon Health in a research note on Wednesday, January 21st. Wells Fargo & Company decreased their price objective on shares of Agilon Health from $1.50 to $1.00 and set an “overweight” rating for the company in a research note on Wednesday, November 5th. Finally, BTIG Research reaffirmed a “neutral” rating on shares of Agilon Health in a research note on Friday, December 12th. Four equities research analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat, Agilon Health currently has an average rating of “Hold” and an average target price of $2.71.

Agilon Health Company Profile

Agilon Health (NYSE: AGL) is a healthcare company that partners with independent primary care physicians to deliver value-based care for Medicare beneficiaries. Through risk-sharing arrangements, Agilon assumes financial responsibility for patient populations, enabling physicians to focus on preventive and proactive health management. The company provides the administrative, clinical and operational infrastructure needed to support comprehensive care delivery.

Agilon’s platform encompasses data analytics, care management, patient engagement tools and population health programs.